Related Experiment Videos
Identification of specific PP2A complexes involved in human cell transformation
Wen Chen1, Richard Possemato, K Thirza Campbell
1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Cancer Cell
|March 5, 2004
Summary
The SV40 small t antigen interacts with protein phosphatase 2A (PP2A). Suppressing a PP2A subunit inhibited phosphatase activity, promoting cell transformation and tumor formation, revealing PP2A
Area of Science:
- Oncology
- Molecular Biology
- Virology
Background:
- The simian virus 40 (SV40) small t antigen (ST) is known to interact with serine-threonine protein phosphatase 2A (PP2A). This interaction is implicated in cellular transformation processes.
- Understanding the specific PP2A subunits involved in SV40-mediated transformation is crucial for deciphering cancer development mechanisms.
Purpose of the Study:
- To investigate the role of the PP2A B56gamma subunit in SV40-induced cellular transformation.
- To determine if modulating PP2A B56gamma activity can affect the tumorigenic potential of cells expressing SV40 antigens.
Main Methods:
- Suppression of the PP2A B56gamma subunit in human embryonic kidney (HEK) cells engineered to express SV40 large T antigen, hTERT, and H-RAS.
- Assessing PP2A-specific phosphatase activity following B56gamma subunit suppression.
- Evaluating anchorage-independent growth and tumor formation capabilities in modified HEK cells.
- Overexpressing the PP2A B56gamma3 subunit in tumorigenic cells and human lung cancer cell lines.
Main Results:
- Suppression of PP2A B56gamma inhibited PP2A-specific phosphatase activity, mimicking the effect of SV40 ST.
- Reduced B56gamma expression conferred anchorage-independent growth and tumor-forming abilities to the engineered HEK cells.
- Overexpression of PP2A B56gamma3 partially reversed tumorigenicity in established cancer cells.
Conclusions:
- Specific PP2A complexes, particularly those involving the B56gamma subunit, play a critical role in human cell transformation.
- Targeting PP2A B56gamma activity represents a potential therapeutic strategy for cancers associated with SV40 or similar oncogenic pathways.